Skewed trial data hid the risk of uncontrollable bleeding
Brilinta is a medication that keeps blood platelets from clotting to prevent unwanted blood clots that can occur with certain heart or blood vessel conditions. This medication lowers the risk of stroke or serious heart problems after a patient has had a heart attack.
Facts about Brilinta
Brilinta manufacturer, AstraZeneca is accused of omitting adverse events such as uncontrollable bleeding from initial trial submission to the FDA. It was discovered that at least 23 instances of people experiencing side effects were left out of the results, and the manufacturer downgraded many adverse events to a lesser side effect.
There isn’t even an antidote for the uncontrollable bleeding. Emergency personnel does not have any options when needing to swiftly reverse the effects of Brilinta. They have to wait for the effects of it to wear off, while their patients continue to bleed.
When manufacturers produce unsafe products that create pain and suffering, you deserve compensation. Although no amount of money will change the fact that you have suffered a serious injury as a result of manufacturer irresponsibility, compensation will help offset your current and future medical costs, as well as provide for the pain and suffering you have experienced. By filing, you may also help protect other men and their families from needless distress.
- Uncontrollable bleeding
- Heart attack
- Severe cardiovascular events
If you or someone you know has suffered an adverse event after using Brilinta, you may be eligible for compensation to ease the financial and emotional burdens you are experiencing. Contact us today to set up a free consultation, during which we will listen to your story, answer any questions you may have and discuss your legal rights and options. If you choose us to represent you, we will work with you on a contingency fee basis; this means you pay nothing until we have secured compensation for you, either through a jury verdict or settlement.
Brilinta’s False Trial Data Hides Uncontrollable Bleeding Risks